|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?显示文摘 | Susan L. Stramer Edward P. Notari David E. Krysztof Roger Y. Dodd | 2013 | Transfusion2013，，： | 2 |
| 2 | Emerging infectious diseases and risks for transfusion safety;past,present and future显示文摘Over the last 10 years,HIV,HCV and HBV have been the focus of blood safety with respect to decreases in infectious disease risks.In addition,screening for WNV RNA and Trypanosoma cruzi antibodies have been introduced in response to risks posed by different exposures in our donor population.HIV,HCV and HBV for the most part share similar transmission routes (i.e.,parenteral and known risk behaviors) and questioning of donors along with increasingly sensitive blood donor screening tests have been responsible for the vast majority of observed reductions in residual risk.For example,since the implementation of HIV-1/HCV NAT in the US,the American Red Cross (ARC) has detected 244 (1:270 000) HCV-infected donors and 32 (1:2 million) HIV-infected donors over the last 10 years of testing of greater than 66 million donations. Current,per-donation residual risks are estimated at 1:1 467 000 for HIV and 1:1 149 000 for HCV[1].Although higher,prior to the widespread implementation of HBV NAT,the HBV per donation residual risk from the same ARC donor population is estimated at 1:280 000-1:357 000[2]. These figures were derived by taking the product of estimated donor incidence of 3-5 per 100 000 person years and remaining window periods that range from 9.1-7.4 days for HIV and HCV,and 30-38 days for HBV.Similar methods for estimates of yield and residual risk have been used worldwide. | Susan Stramer | 2010 | 中国输血杂志2010，23，10： | 2 |
| 3 | Current prevalence and incidence of infectious disease markers and esti- mated window-period risk in the American Red Cross blood donor population显示文摘 | Dodd RY Notari EP Stramer SL | 2002 | Transfusion2002，42，8： | 1 |
| 4 | Transfusion - transmitted infectious diseases 显示文摘 | Allain JP Stramer SL Carneiro - Proietti AB | 2009 | Biologicals2009，2，： | 1 |
| 5 | Nucleic acid testing to detect HBV infection in blood donors显示文摘 | Stramer SL Wend U Candotti D | 2011 | N Engl J Med2011，364，3： | 1 |
| 6 | Lookback on do- nors Who are repeatedly reactive on first-generation hepati- tis C virus assay显示文摘 | Tobler! H Tegmeier G Stramer SL | 2000 | Transfusion2000，40，： | 1 |
| 7 | West nile virus among blood donors in the United States,2003 and 2004显示文摘 | Stramer SL Fang CT Foster GA | 2005 | N End J Med2005，353，： | 1 |
| 8 | Pooled hepatitis B virus DNA testing by nucleic acid amplification:implementation or not显示文摘 | Stramer SL | 2005 | Transfusion2005，45，10： | 1 |
| 9 | Selective reduction of fibrotic markers in repairing corneas of mice deficient in Smad3显示文摘 | Stramer BM Austin JS Roberts All | 2005 | Journal of Cellular Physiology2005，1，23： | 1 |
| 10 | Lookback on donors who are repeatedly reactive on fLrst-generation hepatitis C virus assay 显示文摘 | Tobler LH Tegtmeier G Stramer SL | 2000 | Transfusion2000，，1： | 1 |
| 11 | A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors显示文摘 | Busch MP Glynn SA Stramer SL | 2005 | Transfusion2005，45，2： | 1 |
| 12 | Current preva- lence and incidence of infectious disease markers and esti- mated vido,- period risk in the American Red Cross blood donor population 显示文摘 | DODD R Y NOTARI E P 4th STRAMER S L | 2002 | Transfusion2002，42，： | 1 |
| 13 | Current risks of transfusion-transmitted agents: a review显示文摘 | Stramer SL | 2007 | Arch Pathol Lab Med2007，131，5： | 1 |
| 14 | US NAT Yield:where are we after 2 years?显示文摘 | Stramer SL | 2002 | Transfuse Med2002，12，4： | 1 |
| 15 | Current prevalence and incidence of infectious disease markers and estimated window period risk in the American Red Cross blood donor population显示文摘 | Dodd RY Notari EP Stramer SL | 2002 | Transfusion2002，42，8： | 1 |
| 16 | Prevalence of dengue virus nucleic acid in blood donors in Puerto Rico显示文摘 | Mohadmmed H Stramer SL Tomashek K | 2008 | Transfusion2008，47，3： | 1 |
| 17 | Nes testing strategy to de- tect early HIV-1 infection for use in incidence estimates and or clinical and prevention purposes显示文摘 | Janssen RS Satten GA Stramer SL | 1998 | JAMA1998，280，1： | 1 |
| 18 | Epi-LASIK:preliminary clinical results of an alternative surface ablation procedure显示文摘 | Stramer BM Zieske JD aki MI | 2005 | J Cataract Refract Surg2005，31，5： | 1 |
| 19 | Molecular mechanisms controlling the fibrotic repair phenotype in cornea : implications for surgical outcomes 显示文摘 | Stramer BM Zieske JD Jung JC | 2003 | Invest Ophthalmol Vis Sci2003，44，10： | 1 |
| 20 | Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assay显示文摘 | Tobler LH Tegtmeier G Stramer SL | 2000 | Transfusion2000，40，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员